Drugs /

paclitaxel

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
paclitaxel
Trade Name(s):
Taxol, Asotax, Taxol Konzentrat, Praxel, Bristaxol, and Anzatax
NCI Definition [1]:
A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for paclitaxel

Paclitaxel has been investigated in 365 clinical trials, of which 298 are open and 67 are closed. Of the trials investigating paclitaxel, 2 are early phase 1 (2 open), 78 are phase 1 (52 open), 51 are phase 1/phase 2 (40 open), 157 are phase 2 (132 open), 7 are phase 2/phase 3 (7 open), 65 are phase 3 (61 open), 1 is phase 4 (1 open), and 4 are no phase specified (3 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for paclitaxel clinical trials.

Breast carcinoma, non-small cell lung carcinoma, and malignant solid tumor are the most common diseases being investigated in paclitaxel clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Paclitaxel
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Paclitaxel
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating paclitaxel and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Taxol, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-diacetate 2-benzoate 13-ester with (2r,3s)-n-benzoyl-3-phenylisoserine, paclitaxel (product), benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2ar-(2aalph, 125973, paclitaxel, paclitaxel (substance), 673089, Taxol Konzentrat, Praxel, Bristaxol, Asotax, Anzatax, [2ar-[2a alpha,4beta,4a beta,6beta,9alpha(alphar*,betas*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, taxol, bris, paclitaxel, tax, 22850, paclitaxel [chemical/ingredient], bris taxol, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-diacetate 2-benzoate 13-ester with (2r,3s)-n-benzoyl-3-phenylisoserine, taxol a, onxal, [2ar-[2a alpha,4beta,4a beta,6beta,9alpha(alphar*,betas*),-11alpha,12alpha,12a alpha,12b alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alphar*,betas*),11alpha,1-2alpha,12aalpha,12balpha))-, 33069-62-4, paclitaxel, (2ar-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1h-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, 5beta,20-epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2r,3s)-n-benzoyl-3-phenylisoserine, taxol
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C1411
SNOMED ID [1]:
C-78320

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.